





Figure S2

RBC	11.58+/- 0.8	12.09+/-0.46
Hb	15.58+/- 1.23	14.7+/- 1.34
Hct	58.3+/-4.2	61.35+/- 2.52
Plt	901+/-81.58	928+/-43.5
MPV	5.06+/-0.08	5.13+/-0.14
WBC	10.7+/-0.8	13.03+/-1.6
Neut	0.92+/-0.15	1.40+/-0.42
Lymph	9.06+/-0.6	10.6+/-0.99
Weight (g)	16.6+/-0.8	16.8+/-0.4
Bone marrow cellularity (milions)	22.9 +/- 2.2	22.8+/-4.2

Figure S2 Hematologic Parameters in Mock and Bortezomib treated animals (+/- SEM)

Supplementary Figures:

Figure S1(A): *Bzb does not affect osteoclast function*: Osteoclasts were derived from BMSCs by treatment with MCSF and RANK-L (M/R). TRAP-activity increased with TGF-Beta treatment but was unchanged by addition of Bzb at 1 and 2 nM. (B) Average pit size formed on dentyne by osteoclasts in the presence of 0, 1 and 2nM Bzb. Increasing doses did not affect pit areas (p=n/s).

Figure S2: *Adverse effect profile of Bzb*: Mice treated with 0.3 mg/kg showed no changes in peripheral counts or weight with Bzb treatment versus mice treated with saline for 3 weeks (n=5). No evidence of hematopoietic toxicity or weight loss was seen.